THE ECONOMIC IMPACT OF CYTOMEGALOVIRUS INFECTION AFTER LIVER TRANSPLANTATION
Authors:
- W. Ray KimWKW. Ray Kim
- Andrew D. BadleyABAndrew D. Badley
- Russell H. WiesnerRWRussell H. Wiesner
- Michael K. PoraykoMPMichael K. Porayko
- Eric C. SeabergESEric C. Seaberg
- Michael R. KeatingMKMichael R. Keating
- Roger W. EvansRERoger W. Evans
- E. Rolland DicksonEDE. Rolland Dickson
- Ruud A. F. KromRKRuud A. F. Krom
- Carlos V. PayaCPCarlos V. Paya
- 1 February 2000
- journal article
- clinical trial
- Published by Wolters Kluwer Health in Transplantation
- Vol. 69 (3) , 357-361
Abstract
We studied the economic impact of cytomegalovirus (CMV) disease and its effective reduction with antiviral prophylaxis in liver transplant recipients. Method. Analysis of institutional charge data accumulated during a prospective, randomized, controlled trial comparing oral acyclovir 800 mg four times daily for 120 days (ACV) and intravenous ganciclovir 5 mg/kg every 12 h for 14 days followed by ACV for 106 days (GCV) was performed. Liver transplant recipients who developed CMV disease had significantly higher charges (median: $148,300) than those who developed asymptomatic CMV infection ($119,600) or experienced no CMV infection ($114,100) (P <0.01). A multiple linear regression analysis indicated that CMV disease is associated with a 49% increase in charges, independent of other factors influencing increased hospitalization charges. In CMV-seronegative patients who received a CMV-seropositive donor organ, GCV prophylaxis was associated with a significant reduction in charges, as compared to ACV prophylaxis ($113,900 vs. $153,300, respectively;P =0.02). CMV disease is an independent risk factor for increased resource utilization associated with liver transplantation. The use of an effective prophylactic antiviral regimen provides savings in health care resources, particularly in patients at high risk for developing CMV disease.Keywords
This publication has 20 references indexed in Scilit:
- Randomised trial of efficacy and safety of oral ganciclovir in the prevention of cytomegalovirus disease in liver-transplant recipientsThe Lancet, 1997
- PROPHYLAXIS OF CYTOMEGALOVIRUS INFECTION IN LIVER TRANSPLANTATIONTransplantation, 1997
- Effect of Cytomegalovirus Infection Status on First-Year Mortality Rates among Orthotopic Liver Transplant RecipientsAnnals of Internal Medicine, 1997
- Infections in solid-organ transplant recipientsClinical Microbiology Reviews, 1997
- CYTOMEGALOVIRUS PROPHYLAXIS IN SOLID ORGAN TRANSPLANT RECIPIENTSTransplantation, 1996
- Randomised comparison of ganciclovir and high-dose acyclovir for long-term cytomegalovirus prophylaxis in liver-transplant recipientsThe Lancet, 1995
- Risk factors for cytomegalovirus and severe bacterial infections following liver transplantation: a prospective multivariate time-dependent analysisJournal of Hepatology, 1993
- Interactions of Cytomegalovirus with the Human Immune SystemClinical Infectious Diseases, 1988
- Health Economics: An Introduction for CliniciansAnnals of Internal Medicine, 1987
- Use and Misuse of the Term “Cost Effective” in MedicineNew England Journal of Medicine, 1986